Document:

Exhibit 10.1

 

 

PURSUANT
TO ITEM 601(B)(2)(II) OF REGULATION S-K, CERTAIN INFORMATION

CONTAINED IN THISDOCUMENT, MARKED BY BRACKETS AS [****],
HAS BEEN

OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE

TYPE THAT THE REGISTRANT TREATS AS PRIVATE
OR CONFIDENTIAL.

 

Research
and Collaboration Agreement is made as of the 28 day of January, 2022 (the “Effective Date”) by and between RenovaCare
Inc, a Nevada corporation, having an executive office is at 9375 E. Shea Blvd., Suite 107-A, Scottsdale, AZ 85260
(USA) (the “RCAR”) and HistoCell S.L., a regenerative medicine company, having offices at Parque Tecnologico
801. 2nd Floor, 48160 – Derio (Bezkaia) Spain, (“HistoCell”) (this “Agreement”); each of RCAR
and HistoCell are also referred to individually herein as a “Party” or collectively as the “Parties.”

 

WHEREAS,
RCAR is a public U.S.-based regenerative medicine biotechnology company engaged in the development of cell therapies and medical devices
for the treatment of acute and chronic wounds and skin disorders; and HistoCell is a private Spain-based regenerative medicine company
engaged in adipose cell-derived stem cell therapies and medical devices for the treatment of spinal injuries, acute lung disease, bone
defects, wounds, and skin disorders;

 

WHEREAS,
RCAR and the HistoCell wish to collaborate (the “Collaboration”) [****], and in connection therewith, to undertake
a research and development project on a [****] on the terms and conditions set forth in this Agreement (the “Product”);

 

WHEREAS, in
furtherance of the Collaboration:

 

		·	RCAR has and will provide the expertise of [****];

 

		·	HistoCell has and will provide expertise in the [****];

 

		·	RCAR will provide [****]. and

 

		·	HistoCell will provide [****].

 

ACCORDINGLY,
IT IS HEREBY AGREED AS FOLLOWS:

 

		1	THE RESEARCH AND DEVELOPMENT COLLABORATION

 

		1.1	HistoCell’s contact for the Collaboration
shall be Dr. Begoña Castro, HistoCell’s Chief Scientific Officer. If Dr. Castro is unable or unwilling to continue the supervision
of the Collaboration on behalf of HistoCell, HistoCell shall promptly notify RCAR, and advise it of a suitable successor to Dr. Castro
within [****]calendar days thereafter; RCAR shall not unreasonably
decline to accept the choice of a successor selected in this way; however, if it can demonstrate reasonable grounds for not wanting to
accept the choice of successor, then RCAR may terminate this Agreement by providing notice in accordance with Section 9. 

 

		1.2	RCAR’s contact for the Collaboration shall
be Dr. Roger Esteban-Vives, Vice President of RCAR Product Development. If Dr. Roger Esteban-Vives, is unable or unwilling to continue
the supervision of the Collaboration on behalf of RCAR, RCAR shall promptly notify HistoCell. Dr. Robin Robinson, RCAR Chief Scientific
Officer shall be Dr. Esteban-Vives’ successor. In the event that Dr. Robinson is unable or unwilling to accept such position, RCAR
shall advise HistoCell of a suitable successor to Dr. Robinson within [****]calendar
days thereafter; HistoCell shall not unreasonably decline to accept the RCAR’s choice of successor selected in this way; however,
if it can demonstrate reasonable grounds for not wanting to accept the choice, then HistoCell may terminate this Agreement by providing
notice in accordance with Section 9. 

 

    
	~1~

     

    

		1.3	The Parties must give notice as soon as is practicable to the other Party should there be any changes
to RCAR or HistoCell staff assigned to work on the Collaboration so that the Collaboration will not be negatively affected by such unforeseen
changes.

 

		1.4	Each Party undertakes to supply the levels of data, manpower, materials, resources and commitment identified
as its contribution to the Collaboration in Schedule 1 to this Agreement and shall endeavour to ensure the accuracy of all such
data and promptly correct any error therein of which it becomes aware. For the avoidance of doubt, any data, information or materials
which one Party supplies to the other in the course of the Collaboration shall represent Confidential Information and Background IP (as
each such terms are defined, respectively in Sections 4.4 and 5.1 below), as the case may be, belonging to the supplying
Party.

 

		1.5	The purpose of the Collaboration is to develop
the Product (the “Purpose”); should the Parties agree that they want to jointly commercialize the Product, the Parties
shall enter into a definitive commercialization agreement setting forth, among other things, the financial terms of the joint commercialization
of the Product, the provisions of any cross licensing of a Party’s Solely Owned Research IP (as defined in Section 5.5 )
(the “Definitive Commercialization Agreement”). It is understood and agreed that neither Party is obligated to enter
into a Definitive Commercialization Agreement or any other commercial agreement with each other. However, should any commercial
benefit accrue to a Party (the “Benefiting Party”) from the commercial exploitation of patented Research IP belonging
the Benefiting Party and as to which the Research Personnel of the other Party is identified as an inventor, the Benefiting Party shall
make payments to the other Party, on fair and reasonable terms to be agreed to, in writing, by the Parties, which take due account of
the contribution which both Parties have made to the Collaboration (whether scientific or financial), and all other relevant factors,
such as the use of Background IP and the costs of patenting, licensing, and related business costs. Each Party agrees, understands, and
acknowledges that the other Party is a commercial enterprise and may acquire or develop intellectual property, products, and therapies,
and pursue clinical indications which may conflict with or otherwise make use of Research IP.

 

		1.6	It is contemplated that the Collaboration shall
entail research on the [****]Research is sometimes herein refered
to as the “Research”).

 

		1.7	The initial funding and budget for the [****]shall
be the sole responsibility of HistoCell. The funding and budget for the initial research [****] shall
be the sole responsibility of RCAR. Funding and budget for the co-development and clinical testing of the Product [****].
Each Party shall not participate with any another primary contractor or secondary contractor for substantiall the same proposal covered
by this Agreement (“Proposal (Schedule 1)” and for the work assigned to the primary contractor or secondary contractor
in connection with this Agreement during the Effective Period (as defined in Section 2.1, below).

 

		1.8	The Parties agree to collaborate on the preparation of documents, presentations, and other materials and
to seek outside third-party funding to support the joint development and pilot-scale manufacturing of the Product on the terms and conditions
to be set forth in the Definitive Commercialization Agreement. Development and clinical testing of the Product will be predicated on obtaining
outside funding successfully to support these activities. Notwithstanding the foregoing, any Confidential Information or Background IP
of any Party that is incorporated in the Collaboration may not be used or reversed engineered by the other Party in any manner whatsoever
and no license to such any Confidential Information or Background IP is created hereby or by its ultimate incorporation into the Product
unless otherwise specifically agreed to in writing by the Parties.

 

    
	2

     

    

		1.9	If either Party reasonably believes that the
Collaboration or the way in which a Party is undertaking the Collaboration is deficient or incompatible with the Purpose, it shall notify
the other Party in writing at the earliest possible opportunity, giving full details of the perceived deficiencies. The Parties shall
then discuss the matter in good faith to establish where any deficiencies may lie and an appropriate course of action to deal with them,
as part of which the defaulting Party shall use reasonable efforts to remedy any agreed defaults within an agreed, reasonable period which
shall generally not exceed [****] Business Days the defaulting
Party to remedy any agreed faults, or should the defaulting Party not remedy any agreed faults within the agreed period, then the non-defaulting
Party may terminate this Agreement by providing notice to the defaulting Party in accordance with Section 9.

 

		1.10	The Parties acknowledge that no human subjects are or will be included
in the research undertaken by the Parties pursuant to the Collaboration; however adult human subjects will be enrolled in safety and feasibility
and pivotal efficacy clinical trials planned in the Development phase of the project. Each Party undertakes
to secure all necessary approvals from the competent local and national research ethics committee/s and regulatory authorities that such
Party is obligated to obtain before undertaking any part of the Collaboration, which requires research ethics committee, subjects’
insurance, regulatory authority, and other applicable approvals.

 

		2	DURATION

 

		2.1	This Agreement commences on the Effective Date.

 

		2.2	Subject to earlier termination of this Agreement
as provided in Section 8 below, the term of this Agreement shall
be [****]years commencing on the Effective Date and terminating
on the earlier of the [****] year anniversary of the Effective
Date (the “Effective Period”).

 

		2.3	The Parties periodically shall review the progress of the Collaboration and any possible renewal of this
Agreement no later than one month before the annual anniversary of the Effective Date. If at the end of the Effective Period of the Collaboration
project, it is decided to extend the term of this Agreement, such extension shall be the subject of a formal written amendment to this
Agreement.

 

		3	RECORD KEEPING, REPORTING AND MEETINGS

 

		3.1	The Parties shall share relevant summary data deriving from the Collaboration that relates to the development
of human adipose-derived stem cells and the development of the portable SkinGunTM, on a confidential basis, as described in Section
4 below. The Investigators will make one written report and up to four (4) oral formal presentations summarizing the work completed
each year on the Collaboration project, in addition to any draft manuscripts, posters, or external oral presentation materials.

 

		3.2	As applicable, monthly reporting to the United States government or department or agency thereof (the
“US Government”), as part of a contract or grant, will be prepared by the Investigators (as set forth on Schedule
1 to this Agreement and as may be amended pursuant to Section 10.10) and submitted by RCAR, as the prime contractor; and, as
may be required, the Parties shall also prepare and RCAR shall submit a comprehensive final report to the US Government within ninety
(90) calendar days after the termination of the Agreement. Should either Party be required to file reports with any other government or
agency thereof, each Party shall assist in the preparation and filing of any such reports. Each Party should provide a copy to the other
Party for any such report filed to the US Government or agency.

 

    
	3

     

    

		3.3	For any reports, correspondences and other communications, including invoices submission or claims for payments, made or received by [****],
to or with the US Government in connection with this Agreement, [****]as soon as possible after its occurrence.

 

		4	CONFIDENTIALITY AND PUBLICATION

 

		4.1	The Parties shall ensure that information supplied to or deriving from the Collaboration project is exchanged
between themselves on a confidential basis.

 

		4.2	In the event of one Party (“Disclosing Party”) making available to the other Party
(the “Receiving Party”) Confidential Information (as defined below) relating to its business, scientific or other activities
in the course of the Research and Collaboration, the Receiving Party shall maintain the secrecy of such Confidential Information and that
it shall not use, disclose or grant use of such Confidential Information to any third Person, including: (i) to its staff, employees,
and third party sub-contractors, consultants, or other third party research collaborators engaged to work on, advise on or manage any
aspect of the Collaboration (collectively, “Research Personnel”) except, and only to the extent required to conduct
the research contemplated by this Agreement. Neither Party shall include any of the other Party’s Confidential Information in the
published results of the Collaboration without the prior written permission of that other Party.

 

		4.3	A Receiving Party that receives products, devices or material samples from the Disclosing Party
                                                           shall not reverse engineer such products, devices or analyze samples for chemical or structural composition without the prior
                                                           written consent of the Disclosing Party. The results of all analyses of samples will be regarded as Confidential Information of the
                                                           Disclosing Party and will be treated by the Receiving Party with the same strict confidentiality and restrictions on limited-use and
                                                           disclosure as the other Confidential Information referred to above. The Receiving Party will provide the disclosing Party with a
                                                           written summary of these analyses.

 

		4.4	For purposes of this Agreement
“Confidential Information” shall mean, without
limitation, any data and information that is disclosed by the Disclosing
Party to the Receiving Party, either directly or indirectly in writing, orally, digitally, electronically or by inspection of tangible
or intangible objects, whether marked or not marked as confidential, which includes, but is not limited to trade secrets, inventions (whether
patented or unpatented), technologies, products, services, samples, prototypes, solutions, software, hardware, discoveries, formulas,
processes, know-how, devices, business plans, methods, practices, designs, diagrams, drawings, specifications, records, analyses, test
materials, compounds, materials, formulations, ideas, price lists and other financial information, research data, clinical studies information,
clinical research, personnel and/or customer lists, or other related information and communications, Background IP (as defined in Section
5.1) and the the chemical identity, and any properties or specifications
related to the foregoing, including. Research IP shall be Confidential Information of the Party that owns the Research IP under the terms
set forth in this Agreement.

 

		4.5	Each Party shall ensure that all Research Personnel shall maintain the secrecy of the other Party’s
Confidential Information, and if either Party intends to use the services of sub-contractors, consultants or other third parties to work
on, advise on or manage any aspect of the Research, or intends to reveal any of the results of the Research to any such persons or organizations,
that such Party shall first ensure that all Research Personnel, sign legally-binding agreements undertaking to abide by the same conditions
of confidentiality regarding the Confidential Information as are set out in this Agreement mutatis mutandis, or a joinder agreement
to this Agreement pursuant to which such Research Personnel, to comply with Sections 4, 5, 8.3 and 10.14 of
this Agreement.

 

    
	4

     

    

		4.6	The [****] constitute
Confidential Information of RCAR and [****]held by HistoCell will
be kept in a secure location. Photos or images of the [****]constitute
Confidential Information belonging to RCAR. RCAR is willing to provide images and/or illustrations of the gun for the purpose of scientific
publications and presentations (as described in Section 4.8, below) but these must be approved for such use by RCAR prior to publication.
Any [****]in the possession of HistoCell that are provided by RCAR
or its Affiliates remain the property of RCAR and shall be returned to RCAR upon request or termination of the Agreement. Disposables
[****] will also be returned or destroyed to RCAR’s satisfaction.
None of the [****] will be photographed, sketched, copied, reproduced
or reversed engineered or otherwise utilized by HistoCell without prior written consent by RCAR.

 

		4.7	The [****]and
the instructions for their usage constitute Confidential Information and [****]held
by RCAR will be kept in a secure location. Photos or images of the HistoCell’s [****]constitute
Confidential Information belonging to HistoCell. HistoCell is willing to provide images and/or illustrations of these items for the purpose
of scientific publications and presentations (as described in Section 4.8, below) but these must be approved for such use by HistoCell
prior to publication. Any of these items, accessories, photos, or images in the possession of RCAR that are provided by HistoCell or its
Affiliates remain the property of HistoCell and shall be returned to HistoCell upon request or termination of the Agreement. [****]
or instructions will also be returned or destroyed to the HistoCell’s satisfaction.
None of these items, accessories, other materials, or instructions will be photographed, sketched, copied, reproduced or reversed engineered
or otherwise utilized by RCAR without prior written consent by HistoCell.

 

		4.8	The Parties agree to share jointly all data, documents, instructions, designs, plans, proposals, photos,
images, and other relevant materials on the Product and its development as Confidential Information. Such information will be kept in
secure locations by both parties including shared electronic databases. Publication and review of results from research and development
towards the Product will be subject to joint consent. Such joint materials may be made available as Confidential Information to outside
contractors for consulting, development, manufacturing, and testing funding and investment organizations by mutual consent of the Parties.

 

		4.9	The Parties agree that the existence of this Agreement and its terms will also be considered Confidential
Information and agree not to disclose the terms of this Agreement to a third Person without the prior written consent of the other Party,
except (i) as required to enforce the terms of this Agreement, (ii) to financial institutions, accountants, advisors and legal
counsel to the Parties, (iii) as required by applicable Law, regulatory agencies or the order of a court of competent jurisdiction.
A disclosure of any Confidential Information (i) in response to a valid order by a court or other governmental body or (ii) as
otherwise required by law will not be considered to be a breach of this Agreement or a waiver of confidentiality for other purposes; thereof
to the owner Party to enable the owner Party to seek a protective order or otherwise prevent such disclosure.

 

		4.10	The obligations in this Section 4 above shall not apply to data or information which the Receiving
Party can clearly demonstrate:

 

(a) was known to the Receiving Party
prior to disclosure; or

 

(b) was or becomes part
of the public domain through no fault of the Receiving Party; or

 

(c) becomes lawfully
available to the Receiving Party from an unconnected third party who is under no obligation of confidentiality in respect thereof, or
with the lawful right to make such disclosure; or

 

    
	5

     

    

(d) has been independently
developed or conceived for or by it without reference to the other Party’s Confidential Information; or

 

(e) it is required to
disclose by applicable Law or a regulatory body, in which circumstances the Receiving Party shall wherever practicable give reasonable
advance notice of the intended disclosure to the other Party, and the relaxation of the obligations of confidentiality shall apply only
for as long as is necessary to comply with the relevant law or regulatory requirement and solely for the purposes of such compliance.

 

		4.11	The obligations of confidentiality set forth herein as to any item of Confidential Information shall survive
the expiration or earlier termination of this Agreement until such item of Confidential Information would no longer qualify as “Confidential
Information” under the terms of this Agreement.

 

		5	OWNERSHIP OF INTELLECTUAL PROPERTY

 

		5.1	Nothing in this Agreement shall affect the ownership
of intellectual property rights of either Party existing prior to this Agreement or generated outside the Collaboration (“Background
IP”). Neither Party shall knowingly make Background IP available to the other Party (i) which it does not have the right to
make available to that Party, (ii) where it does not have the right to grant the licences to use such Background IP as contemplated by
this Agreement or, (iii) where to do so would cause an infringement of the rights of a third party. For the avoidance of doubt, Background
IP belonging to RCAR (the “RCAR Background IP”) includes but is not limited to; the [****] RCAR
Confidential Information, and the technology contained within the [****].
Background IP belonging to HistoCell (the “HistoCell Background IP”) includes but is not limited to HistoCell’s
[****] materials and methodology and descriptions of the same,
and HistoCell Confidential Information.

 

		5.2	If one Party makes any of its Background IP available to the other
Party in the course of the Research and Development Collaboration, the Party receiving such Background IP shall treat it as Confidential
Information disclosed hereunder and shall not disclose it to a third party nor use it for any purposes other than that for which it was
made available to that Party. Neither Party has an obligation to provide Background IP that they do not wish to provide. Except as otherwise
expressly provided in this Agreement, under no circumstances shall a Party, as a result of this Agreement, obtain any ownership interest,
license or other right, title, or interest in or to any Background IP or other intellectual property or Confidential Information of the
other Party, including its Solely Owned Research IP (as that term is defined in Section 5.5 below), whether by implication, estoppel,
or otherwise, including any items controlled or developed by the other Party, or delivered by the other Party, at any time pursuant to
this Agreement.

 

		5.3	Should one Party become aware of any infringement of any Background IP, it shall notify the other Party
as soon as is reasonably practicable upon such infringement coming to its notice, and the Party owning such Background IP shall have the
sole conduct of any proceedings with relation to its own Background IP. Each Party shall indemnify and hold harmless the other Party against
all liability for any loss, damages, costs, claims or demands of any nature whatsoever incurred or suffered by it in respect of any claim
or action stating that the use of the such Background IP infringes the intellectual property rights of any third party (“Intellectual
Property Infringement”) in the course of the Collaboration provided that the other Party:

 

		(a)	gives it notice of any Intellectual Property Infringement promptly upon becoming aware thereof.

 

    
	6

     

    

		(b)	gives it the sole conduct of the defence of any claim or action in respect of an Intellectual Property
Infringement and does not at any time admit liability or otherwise settle or compromise the said claim or action except upon the express
instructions of the Party owning the Background IP in question; and

 

		(c)	acts in accordance with the reasonable instructions of the Party owning the said Background IP and gives
it such assistance as it shall reasonably require with regard to the conduct of such defence.

 

		5.4	Each Party shall keep appropriate records and documentation concerning Research IP (as defined in Section
5.5 below) and disclose to the other Party all Research IP, including copies of all invention disclosures and other similar documents
created in the ordinary course of its business that disclose any conception or reduction to practice of any intellectual property constituting
Research IP. A Party shall make all such disclosures to the other Party at least thirty (30) Business Days before any public disclosure
of such Research IP or any required submission to government agencies in compliance with the requirements of government supported research.
Each Party shall maintain contemporaneous, complete, and accurate written records of its (or its Research Personnel) activities concerning
Research IP that provide proof of the conception date and reduction to practice date of any Research IP for which any of its Research
Personnel claim inventorship status.

 

		5.5	For purposes of this Agreement, “Research IP” means all Intellectual Property made,
invented, developed, created, conceived, or reduced to practice by any Party, a Party’s Research Personnel or any affiliate of any
of the foregoing (i) as a result of work conducted pursuant to this Agreement, (ii) or by a Party in its evaluation, use, or implementation
of the other Party’s Background IP or Confidential Information, or (iii) by a receiving Party resulting from or derived from or
based on the other Party’s Background IP or Confidential Information, in each case, including all rights in any patents or patent
applications, copyrights, trade secrets, and other intellectual property rights relating thereto.

 

		5.6	Regardless of inventorship, as between the Parties:

 

		(a)	RCAR shall
own all right, title, and interest in and to Research IP relating to, derived from, based upon or constituting an improvement to,
any RCAR Background IP (the “RCAR Solely Owned Research IP”);
	 	 	 
	 	(b)	HistoCell
shall own all right, title, and interest in and to Research IP relating to, derived from, based upon or constituting an improvement
to, any HistoCell Background IP (the “HistoCell Solely Owned Research IP”);
	 	 	 
	 	(c)	RCAR
Solely Owned Research IP and HistoCell Solely Owned Research IP are collectively herein sometimes referred to as “Solely
Owned Research IP.”
	 	 	 
	 	(d)	The Parties, shall use Commercially Reasonable Efforts to address all issues concerning the inventorship or ownership of, or any rights
to, Research IP in a fair and equitable manner and in accordance with the requirements of U.S. patent law to achieve the goals
of the Collaboration.

 

		5.7	The Party owning Solely Owned Research IP:

 

		(a)	will have
the exclusive right, but not the obligation, to prepare, file, prosecute, and maintain patent applications and patents covering its
solely owned Research IP;

    
	7

     

    

	 	(b)	will be
the sole Prosecuting Party for such Solely Owned Research IP; and
	 	 	 
	 	 (c)	shall
keep the other Party currently informed of developments concerning the filing and prosecution of all patent applications, amendments,
and other documents relating to Solely Owned Research IP. Anything in the foregoing to the contrary notwithstanding Prosecuting Party shall not be required to provide the other Party with any copies of
any filings made by it with respect to its Solely Owned Research IP.

 

		5.8	At the written request of a Prosecuting Party, the non-Prosecuting Party shall make its representatives,
including its Research Personnel, reasonably available to the Prosecuting Party to the extent necessary/useful to assist the Prosecuting
Party in the preparation, filing, prosecution, and maintenance of patent applications and patents, as well as any infringement litigation,
concerning Research IP. The non-Prosecuting Party shall execute and deliver to the Prosecuting Party all descriptions, applications, declarations,
assignments, and other documents and instruments necessary in carrying out the provisions of this Section 5.8.

 

		5.9	Each Party is solely responsible for all costs and expenses relating to the preparation, filing, and prosecution
of patent applications claiming Solely Owned Research IP by it and the maintenance of any resulting patents.

 

		5.10	HistoCell hereby assigns and agrees to assign to RCAR all of its right title and interest in and to any
and all RCAR Solely Owned Research IP the ownership of which belongs, in accordance with the terms of this Agreement, to RCAR. RCAR hereby
assigns and agrees to assign to HistoCell all of its right title and interest in and to any and all HistoCell Solely Owned Research IP
the ownership of which belongs, in accordance with the terms of this Agreement, to HistoCell.

 

		5.11	Each Party agrees to ensure that any of its Research Personnel who works on or provides services in connection
with the Collaboration on behalf of such Party, is legally bound by written agreement requiring such Research Personnel to:

 

(a) follow that Party’s policies
and procedures for reporting any inventions, discoveries or other Research IP invented, conceived, developed, derived, discovered, generated,
identified, or otherwise made by the Participating Individual that arises from access to Confidential Information of either Party and
that relates to the Research or the Background IP;

 

(b) assign to RCAR and/or HistoCell, as
the case may be, all of their right, title, and interest in and to any Research IP constituting RCAR Solely Owned Research IP or HistoCell
Solely Owned IP, as the case may be, under this Agreement, including all intellectual property rights relating thereto; and, during and
after such Research Personnel’s engagement with such Party, agrees to reasonably cooperate with such Party to (i) apply for, obtain,
perfect, and transfer to such Party any and all intellectual property rights and interests into the Research IP in any jurisdiction in
the world as far as allowed by applicable laws in such jurisdiction; and (ii) cooperate in maintaining, protecting, defending and enforcing
the same, including, without limitation, executing and delivering to such Party any and all applications, oaths, declarations, affidavits,
waivers, assignments, and other documents and instruments as shall be requested by such Party in connection with the filing and enforcement
of any patent or other rights in the Research IP;

 

(c) perform all acts and sign, execute,
acknowledge, and deliver any and all papers, documents, and instruments required to fulfill the obligations and purposes of that agreement;
and,

 

    
	8

     

    

(d) be bound by obligations of confidentiality
and non-use no less restrictive than those set out in this Agreement.

 

		5.12	In addition,
(a) HistoCell shall ensure, that any of its Research Personnel involved or engaged in any aspect of the Research, including, but not limited
to the Research Personnel, by legally binding agreement, has assigned their respective intellectual property rights in and to any RCAR
Solely Owned Research IP to, or are under an obligation to assign their rights thereto, to RCAR and (b) RCAR shall ensure, that any of
its Research Personnel involved or engaged in any aspect of the Research, including, by legally binding agreement, has assigned their
respective intellectual property rights in and to any HistoCell Solely Owned Research IP to, or are under an obligation to assign their
rights thereto, to HistoCell.

 

		5.13	Subject to the terms and conditions of this Agreement:

 

(a) RCAR , on behalf
of itself and its Affiliates, hereby grants to HistoCell during the term of thisAgreement a fully paid up, non-exclusive, royalty-free,
non-transferable license under the RCAR Background IP and RCAR Solely Owned Research IP for
the sole purpose of enabling, and only to the extent necessary to enable, HistoCell to perform its responsibilities and development
obligations under this Agreement and not for any commercial purpose; and

 

(b) HistoCell, on behalf
of itself and its Affiliates, hereby grants to RCAR during the Term of this Agreement a fully paid up, non-exclusive, royalty-free, non-transferable
license under the HistoCell Background IP and HistoCell Solely Owned Research IP for
the sole purpose of enabling, and only to the extent necessary to enable, RCAR to perform its responsibilities and development
obligations under this Agreement and not for any commercial purpose .

 

(c) The foregoing licenses
shall terminate automatically upon the termination or expiration of this Agreement. Except as expressly provided in this Section 5.11(b)
neither Party acquires any rights nor licenses, express or implied, in, to or under the Background IP of the other Party.

 

	5.14	Except
as otherwise expressly provided in this Agreement, under no circumstances shall a Party, as a result of this Agreement, obtain any ownership
interest or other right, title, or interest in or to any other Background IP, Solely Owned Research IP or Confidential Information of
the other Party, whether by implication, estoppel, or otherwise, including any items controlled or developed by the other Party, or delivered
by the other Party, at any time pursuant to this Agreement. For purposes of this definition only, “controlled” means, with
respect to any Background IP, Solely Owned Research IP or Confidential Information, the possession of (whether by ownership or license,
other than pursuant to this Agreement) or the ability of a Party and/or its Affiliates to grant the other Party access, a license, or
a sublicense to Intellectual Property or Confidential Information on the terms and conditions set forth in this Agreement without requiring
a third Party's consent, or violating the terms of any agreement or other arrangement with or obligation to a third Party existing at
the time such Party and/or its Affiliates would be required under this Agreement to grant the other Party such access, license, or sublicense.
	 	 
	5.15	This Agreement is intended to and hereby does serve, among other things, as a “joint research agreement”
for purposes of Section 102(c) of the US Patent Act, 35 U.S.C. § 102(c). Each Party shall provide the other Party with all reasonable
assistance and cooperation, including the preparation and filing of any terminal, or statutory, disclaimers and other documents, required
to procure and preserve the protections under the Patent Act for all Research IP developed under the terms of this Agreement. Each Party
is solely responsible for all costs and expenses relating to the preparation, filing, and prosecution of patent applications claiming
Solely Owned Research IP by it and the maintenance of any resulting patents.

 

    
	9

     

    

		6	LIABILITIES AND INDEMNITIES

 

		6.1	Each Party shall fully and effectively indemnify the other Party and its employees, directors, consultants,
third-party contractors, representatives and agents and keep them fully and effectively indemnified for all liabilities arising from its
own acts, omissions or defaults under this Agreement, including but not limited to, all liabilities arising from actions by any of the
Research Personnel engaged by an indemnifying Party participating in the Collaboration and the use to which it or its Research Personnel
puts Research IP or Background IP belonging to the other Party. Notwithstanding any other provision of this Agreement, each Party shall
use its reasonable endeavours to mitigate losses it may incur that are covered by indemnities provided by the other Party.

 

		6.2	The Parties shall carry out the Collaboration in accordance with accepted scientific and industry principles
and standards and shall endeavour to ensure the accuracy of the results of the results of the Collaboration. However, the Parties recognise
that this Agreement provides for the carrying out of experimental research and development activities that Research IP or Background IP
may contain experimental materials, data or processes whose properties and safety may not have been established. Therefore, the Parties
do not undertake that the Research will provide specific results or provide data which can be used for a particular purpose, and any Research
IP, Background IP, information or materials which a Party provides under this Agreement are supplied “as is” and without any
express or implied warranties, representations or undertakings. A Party shall not be liable for the consequences or effects of any use
to which the other Party or any third party may put Research IP, except to the extent that such claims arise from the proven negligence
or default of the providing Party or its Research Personnel.

 

		6.3	The Parties undertake to make no claim in connection with this Agreement or its subject matter against
any employees, agents or appointees of the other Party (apart from claims based on fraud or wilful misconduct). This undertaking is intended
to give protection to individual researchers and officers and does not prejudice any right which the Parties might have to claim against
the other Party.

 

		6.4	To the fullest extent permitted by Law the terms and conditions in this Agreement are agreed to be in
place of any warranties, obligations or conditions implied by law, trade usage, custom or otherwise as to the merchantable quality or
the fitness for any particular purpose of the services or items being supplied hereunder. Nothing in this Agreement limits or excludes
either the liability of either of Party for death or personal injury, any fraud or for any sort of liability that by Law cannot be limited
or excluded, or any loss or damage caused by a deliberate breach of this Agreement.

 

		7	FORCE MAJEURE

 

		7.1	Neither Party will be liable for any failure or delay in performing an obligation under this Agreement
that is due to any of the following causes (which events and/or circumstances are hereinafter referred to as “Force Majeure”),
to the extent beyond its reasonable control: acts of God, accident, riots, war, terrorist act, epidemic, pandemic, quarantine, civil commotion,
breakdown of communication facilities, breakdown of web host, breakdown of internet service provider, natural catastrophes, governmental
acts or omissions, changes in laws or regulations, national strikes, fire, explosion, generalized lack of availability of raw materials
or energy; provided that the parties stipulate that Force Majeure shall not include the novel coronavirus Covid-19 pandemic which is ongoing
as of the date of the execution of this agreement. If such circumstances persist for three months or longer, either Party may terminate
this Agreement forthwith by giving notice in writing to that effect to the other Party.

 

    
	10

     

    

		7.2	For the avoidance of doubt, Force Majeure shall not include (a) financial distress nor the inability of
either party to make a profit or avoid a financial loss, (b) changes in the market prices or conditions, or (c) a Party’s financial
inability to perform its obligations hereunder.

 

		8	TERMINATION

 

		8.1.	This Agreement shall automatically terminate
on (i) the [****]anniversary date of the Effective Date or (ii)
the [****]month anniversary of the Effective Date if the Parties,
individually or collectively, have not secured third-party funding for the Collaboration.

 

		8.2	This Agreement may be terminated or extended at any time by mutual
written agreement of the Parties.

 

		8.3	Anything in Section 8.1 to the contrary notwithstanding either Party may terminate this Agreement
effective immediately upon giving written notice, in accordance with Section 9, to the other Party if:

 

(a)
the other Party is in breach of its obligations under this Agreement, and fails to remedy such breach within [****]
Business Days of receiving notice from the Party not in breach which
clearly identifies and gives details of the breach; 

 

(b) the other Party enters into bankruptcy
or liquidation, has a receiver, liquidator or administrator appointed over the whole or any part of its assets, becomes insolvent or is
otherwise unable to pay its debts as they fall due (with the exception of liquidation for the specific purpose of an amalgamation, reconstruction
or other reorganisation such that the body resulting from the reorganisation agrees to be bound by and to assume the obligations imposed
on the correspondent Party herein mutatis mutandis);

 

(c) there has been a demonstrable lack of progress or poor
performance by the other Party;

 

(d) the other Party enters into a consolidation, merger or
other corporate transaction, including an agreement for the sale of substantially all of its assets;

 

(e) termination is pursuant to Sections 1.1, 1.2,
1.9, 7.2 or on the basis of a violation of Section 10.11; and

 

(f) entry into a research and development collaboration agreement
by either Party where such agreement might be in conflict with or supersede this Agreement or create a conflict of interest between the
Parties.

 

To avoid any
ambiguity, termination pursuant to this Section 8.2 shall be effective as of the date of the notice of termination.

 

		8.4	Upon termination of this Agreement as per the provisions contained herein, each Party cease to use, and
shall promptly return, all technical and scientific information, materials and devices (including Confidential Information and Background
IP) supplied to it hereunder in connection with the Research by the other Party, together with all copies thereof in its possession, or
in the possession of any of its related companies, Affiliates, successors in title, assigns or sub-licensees. The rights, benefits and
licences granted or agreed to be granted hereunder to the Party in receipt of such notice shall automatically be deemed terminated or
cease forthwith upon such termination and any rights assigned or agreed to be assigned (except as to the assignment of RCAR Solely Owned
Research IP and the HistoCell Solely Owned Research IP, as the case may be) shall automatically be reassigned to the Party that owns them.

 

    
	11

     

    

		8.5	The exercise by either Party of a termination right provided for under this Agreement shall not give rise
to the payment of damages or any other form of compensation or relief to the other Party with respect thereto.

 

		8.6	On termination or expiration of this Agreement, the Parties will have no obligation to continue further
work in the Collaboration.

 

		8.7	Termination or expiration of this Agreement for any reason shall not release either Party from any liability
or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the
extent it is expressly stated to survive such termination. Termination or expiration of this Agreement for any reason shall not constitute
a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or
otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration. Except as set
forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement
shall survive expiration or termination of this Agreement: Sections 1.5, 1.8, 3.2, 4, 5, 6,
8.3, 8.4, 8.5, 8.6, 9, and 10.

 

		9	NOTICES

 

All notices, requests,
consents, claims, demands, waivers, and other communications hereunder shall be in writing and shall be deemed to have been given in accordance
with this Section 9:

 

For
RCAR:

 

RenovaCare, Inc.

9375 E. Shea Blvd.

Suite 107-A

Scottsdale, AZ 85260

United States of
America

Attention: Dr. Robin
Robinson, Chief Scientific Officer

Phone: 240-330-9951

Facsimile: 301-349-4035

Email Address: rrobinson@renovacareinc.com

 

With a copy to Joseph
Sierchio (which shall not be deemed notice hereunder)

 

Sierchio Law, LLP

29 Reed Road

Valatie, New York
12184

United States of
America

Email: joseph@sierchiolaw.com

 

For HistoCell:

 

Dr. Julio Font, Chief Executive Officer

Parque Tecnologico 801. 2nd
Floor

48160 – Derio, Bizkaia

Spain

 

Tel: +34 94 656 7900

Fax: +34 94 403 69 99

Email: font@histocell.com

 

    
	12

     

    

Notices sent in accordance
with this Section 9 shall be deemed effectively given: (a) when received, if delivered by hand (with written confirmation of receipt);
(b) when received, if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail
(in accordance with this Section 9), in each case, with confirmation of transmission, if sent during normal business hours of the
recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) on the [****]Business Day
after the date mailed, by certified or registered mail, return receipt requested, postage prepaid.

 

		10	GENERAL

 

		10.1	This Agreement, including its Proposal (Schedule 1), supersedes and terminates all other agreements,
terms, understandings and representations regarding the Collaboration project whether written, oral, express or implied between the Parties
and constitutes the entire agreement between the Parties concerning the Research and the sole basis on which they have entered into this
Agreement. However, this Section shall not exclude a Party’s liability for any fraudulent representation or concealment made prior
to the execution of this Agreement. In the event of any conflict or contradiction between the terms in the main body of this Agreement
and Proposal (Schedule 1), the terms in the main body of this Agreement shall prevail.

 

		10.2	Each Party shall ensure that its work on the Collaboration project complies fully with all applicable
local, government and international laws, regulations and guidelines which are effective during the period of this Agreement, including
those governing health and safety, data protection and equal opportunities matters such as race and gender equality, disability, age,
religion and sexual orientation. In the event that a necessary ethical approval (if any) for the use of any material in the Proposal (Schedule
1) expires, is revoked or is not approved, the Parties agree that that they would not be able to make use of that material and the
Parties would discuss alternatives.

 

		10.3	If any part or any provision of this Agreement proves to any extent to be invalid, illegal or unenforceable,
the remainder of such provision and all other provisions of this Agreement shall remain valid and enforceable to the fullest extent permissible
by law and regulation, and such provision shall be deemed to be omitted from this Agreement to the extent of such invalidity, illegality
or unenforceability. The remainder of this Agreement shall continue in full force and effect and the Parties shall negotiate in good faith
to replace the invalid, illegal or unenforceable provision with a valid, legal and enforceable provision which has an effect as close
as possible to the provision or terms being replaced.

 

		10.4	No failure to exercise or delay in the exercise of any right or remedy which any Party may have under
this Agreement or in connection with this Agreement shall operate as a waiver thereof, and nor shall any single or partial exercise of
any such right or remedy prevent any further or other exercise thereof or of any other such right or remedy.

 

    
	13

     

    

		10.5	Except as provided for herein, neither Party shall use the other’s name, crest, logo or trademarks,
or the name of any of its Research Personnel, nor imply their identity, without the express written permission of that Party or individual,
except that nothing in this Section shall restrict, delay, impede or prevent a Party from using the other Party’s name when making
disclosures under the any legally required filing or report, or in its own reports or internal literature. The content and timing of any
internet or press releases regarding the Research shall be agreed by both Parties, such agreement not unreasonably to be withheld.

 

		10.6	Except as otherwise expressly provided for in this Agreement, nothing in this Agreement shall confer or
purport to confer on any third party any benefit or any right to enforce any term of this Agreement and it shall not require the permission
of any third party for it to be amended or terminated.

 

		10.7	This
Agreement, originally written in the English language, shall be governed by the English language.
In the event any dispute arises with respect to this Agreement, the meanings of all terms and provisions of this Agreement shall be interpreted
in their original English form. All notices required or permitted to be given hereunder, and all written, electronic, oral or other
communications between the Parties regarding this Agreement shall be in the English language.

 

		10.8	For purposes of this Agreement, (a) Section headings,
if any, in this Agreement are used for convenience only and shall not affect its interpretation or construction and shall not constitute
part of this Agreement; (b) the words “include,” “includes,” and “including” shall be deemed to be
followed by the words “without limitation”; (c) the word “or” is not exclusive; (d) the words “herein,”
“hereof,” “hereby,” “hereto,” and “hereunder” refer to this Agreement as a whole;(e) all
references in this Agreement to the singular shall include the plural where applicable, and all references to gender shall include both
genders and the neuter;(f) all references to days in this Agreement
mean calendar days, unless otherwise specified; and (g) unless otherwise
specified, references in this Agreement to any article shall include all sections, subsections, and paragraphs in such article; references
in this Agreement to any section shall include all subsections and paragraphs in such sections; and references in this Agreement to any
subsection shall include all paragraphs in such subsection.

 

This Agreement shall be construed without
regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument
to be drafted. Any Schedules referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent
as if they were set forth verbatim herein. The recitals to this Agreement shall constitute a part of this Agreement.

 

		10.9	This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective
successors in title and assigns, and any amendments to this Agreement shall be agreed in writing by all Parties, their successors in title
or their assigns.

 

		10.10	This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each
Party hereto. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed
by the waiving Party. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy,
power, or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise
of any right, remedy, power, or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right,
remedy, power, or privilege.

 

		10.11	Neither Party shall assign or otherwise transfer any of its rights, or delegate or otherwise transfer
any of its obligations or performance, under this Agreement, in each case whether voluntarily, involuntarily, by operation of law or otherwise,
without the other Party's prior written consent, which consent may be given or withheld in that Party's sole discretion. For purposes
of the preceding sentence, and without limiting its generality, any merger, consolidation, or reorganization involving a Party (regardless
of whether that Party is a surviving or disappearing entity) shall be deemed to be a transfer of rights, obligations, or performance under
this Agreement for which the other Party's prior written consent is required. No delegation or other transfer will relieve the other Party
of any of its obligations or performance under this Agreement. Any purported assignment, delegation, or transfer in violation of this
Section 10.11 is void. This Agreement is binding upon and inures to the benefit of the Parties hereto and their respective permitted
successors and assigns.

 

    
	14

     

    

		10.12	This Agreement, together with all Schedules and any other documents incorporated herein by reference,
constitutes the sole and entire agreement of the Parties to this Agreement with respect to the subject matter contained herein, and supersedes
all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event
of any conflict between the terms and provisions of this Agreement and those of any Schedule or other document, the following order of
precedence shall govern: (a) first, this Agreement, excluding its Schedules; (b) second, the Schedules to this Agreement as of the Effective
Date; and (c) third, any other documents incorporated herein by reference.

 

		10.13	Neither Party shall issue or release any announcement, statement, press release, or other publicity or
marketing materials relating to this Agreement, or, unless expressly permitted under this Agreement, otherwise use the other Party's trademarks,
service marks, trade names, logos, domain names, or other indicia of source, association, or sponsorship, in each case, without the prior
written consent of the other Party, which shall not be unreasonably withheld or delayed.

 

		10.14	Each Party shall, and cause its Research Personnel, upon the reasonable request of the other Party and
at the sole cost and expense, of the other Party, to promptly execute such documents and perform such acts as may be necessary to give
full effect to the terms of this Agreement.

 

		10.15	The relationship between the Parties is that of independent contractors. Nothing contained in this Agreement
shall be construed as creating any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship
between the Parties, and neither Party shall have authority to contract for or bind the other Party in any manner whatsoever.

 

		10.16	This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of
which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail, or other
means of electronic transmission (to which a PDF copy is attached) shall be deemed to have the same legal effect as delivery of an original
signed copy of this Agreement.

 

		10.17	In this Agreement the following terms shall have the meaning ascribed thereto below:

 

“Affiliate"
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such Person. For purposes of this definition only, the term “control” means the power to direct
or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or
otherwise/direct or indirect ownership of more than fifty percent (50%) of the voting securities of a Person, and “controlled by”
and “under common control with” have correlative meanings.

 

“Agreement”
shall have the meaning ascribed to it in the preamble to this Agreement.

 

“[****]”
shall have the meaning ascribed to it in Section 1.6.

 

    
	15

     

    

“Background
IP” shall have the meaning ascribed to it in Section 5.1.

 

“Business
Day” means a day other than a Saturday, Sunday, or other day on which commercial banks in New York City, United States of America
or Barcelona, Spain are authorized or required by Law to be closed for business.

 

“Collaboration”
shall have the meaning ascribed to it in the Recitals to this Agreement.

 

“Commercially
Reasonable Efforts” means the carrying out of a party's obligations under this Agreement with the exercise of prudent scientific
and business judgment and a level of effort and resources consistent with the efforts, and resources that the Party who bears the performance
obligation or a comparable third party in the regenerative medicine industry would employ for products of similar strategic importance
and commercial value that result from its own research efforts. Commercially Reasonable Efforts includes: (a) promptly assigning responsibility
for development activities to specific employees who are held accountable for progress and monitoring such progress on an on-going basis;
(b) setting and consistently seeking to achieve specific and meaningful objectives and timelines for carrying out such development activities;
(c) consistently making and implementing decisions and allocating resources designed to advance the progress of such objectives and timelines;
and (d) employing compensation systems for its employees that are no less favorable than the compensation systems the party applies with
respect to its other programs with technology [and/or] products of similar potential.

 

“Confidential
Information” shall have the meaning ascribed to it in Section 4.3.

 

“Definitive
Commercialization Agreement” shall have the meaning ascribed to it in Section 1.5.

 

“Disclosing
Party” shall have the meaning ascribed to it in Section 4.2.

 

“Effective
Date” shall have the meaning ascribed to it in Section 2.1.

 

“Effective
Period” shall have the meaning ascribed to it in Section 2.1.

 

“Force Majeure”
shall have the meaning ascribed to it in Section 7.1.

 

“HistoCell”
shall have the meaning ascribed to it in the preamble to this Agreement.

 

“HistoCell
Background IP” shall have the meaning ascribed to it in Section 5.1.

 

“HistoCell
Solely Owned Research IP” shall have the meaning ascribed to it in Section 5.6.

 

“[****]”
shall have the meaning ascribed to it in the recitals to this Agreement.

 

“Information”
means any and all ideas, concepts, data, know-how, discoveries, improvements, methods, techniques, technologies, systems, specifications,
analyses, products, practices, processes, procedures, protocols, research, tests, trials, assays, controls, prototypes, formulas, descriptions,
formulations, submissions, communications, skills, experience, knowledge, plans, objectives, algorithms, reports, results, conclusions,
and other information and materials, irrespective of whether or not copyrightable or patentable and in any form or medium (tangible, intangible,
oral, written, electronic, observational, or other) in which such Information may be communicated or subsist. Without limiting the foregoing
sentence, Information includes any technological, scientific, business, legal, patent, organizational, commercial, operational, or financial
materials or information.

 

    
	16

     

    

“Intellectual
Property” means all patentable and unpatentable inventions, works of authorship or expression, including computer programs,
data collections and databases, and trade secrets, and other Information.

 

“Intellectual
Property Infringement” shall have the meaning ascribed to it in Section 5.3.

 

“Investigator(s)”
means the Person(s) appointed by the Parties pursuant to Sections 1.1 and 1.2.

 

“Law”
means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement
or rule of law of any federal, state, local, or foreign government or political subdivision thereof, or any arbitrator, court, or tribunal
of competent jurisdiction.

 

“Party”
and “Parties” shall have the meaning ascribed to them in the preamble to this Agreement.

 

“Person”
means an individual, corporation, partnership, joint venture, limited liability entity, governmental authority, unincorporated organization,
trust, association, or other entity.

 

“Portable
SkinGunTM Research” shall have the meaning ascribed to it in Section 1.6.

 

“Product”
shall have the meaning ascribed to it in the recitals to this Agreement.

 

“Prosecuting
Party” means the Party owning Solely Owned Research IP.

 

“Purpose”
shall have the meaning ascribed to it in Section 1.5.

 

“RCAR”
shall have the meaning ascribed to it in the preamble to this Agreement.

 

“RCAR Background
IP” shall have the meaning ascribed to it in Section 5.1.

 

“RCAR Solely
Owned Research IP” shall have the meaning ascribed to it in Section 5.6.

 

“Research”
shall have the meaning ascribed to it in Section 1.6.

 

“Research
IP” shall have the meaning ascribed to it in Section 5.5.

 

“Research
Personnel” shall have the meaning ascribed to it in Section 4.2.

 

“[****]”shall
have the meaning ascribed to it in the recitals to this Agreement.

 

“Solely Owned
Research IP” shall have the meaning ascribed to it in Section 5.6.

 

“US Government”
shall have the meaning ascribed to it in Section 3.2.

 

		10.18	EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY
OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR
NON-INFRINGEMENT WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT INCLUDING, WITHOUT LIMITATION, CONFIDENTIAL INFORMATION, INTELLECTUAL
PROPERTY RIGHTS, TECHNOLOGY, RESEARCH IP, INDEPENDENT TECHNOLOGY, MATERIALS, PRODUCTS AND THE LIKE, OR ANY PORTION OF COMPONENT THEREOF.

 

    
	17

     

    

		10.19	This Agreement and all related documents, and all matters arising out of or relating to this Agreement,
are governed by, and construed in accordance with, the laws of the State of New York, United States of America without regard to the conflict
of law provisions thereof to the extent such principles or rules would require or permit the application of the laws of any jurisdiction
other than those of the State of New York In the event of any controversy or claim arising out of or relating to this contract, or the
breach thereof, either Party may, by written notice to the other, have such dispute referred to their respective executive officers for
attempted resolution by negotiation in good faith. Such attempted resolution shall take place no later than [****]days following
receipt of such notice. If the Parties are unable to resolve a dispute, despite using reasonable efforts to do so, then the parties hereto
agree first to try and settle the dispute by mediation, administered by the International Centre for Dispute Resolution under its Mediation
Rules. If settlement is not reached within [****] days after service of a written demand for mediation, any unresolved controversy
or claim arising out of or relating to this contract shall be settled by arbitration in accordance with the International Arbitration
Rules of the International Centre for Dispute Resolution. Notwithstanding anything contained above to the contrary, issues involving the
validity of patents will be decided by the courts or patent offices of the country which issued the patents in question.

 

 

[SIGNATURES APPEAR
ON THE FOLLOWING PAGE]

[BALANCE OF THIS
PAGE WAS LEFT INTENTIONALLY BLANK]

 

 

 

 

 

 

    
	18

     

    

 

	Signed for and on behalf of	Signed for and on behalf of
	HistoCell S.L.	RenovaCare Inc.
	 	 
	 	 
	 	 
	/S/ Julio Font	/s/ Robin Robinson
	....................................	......................................
	Name: Dr. Julio Font	Name: Dr. Robin Robinson
	Title: Chief Executive Officer	Title: Chief Scientific Officer
	 	 
	 	 
	Date January 28, 2028	Date January 28, 2028

 

 

 

 

 

 

 

 

    
	19

     

    

 

Schedule
1

To The Research
and Collaboration Agreement 

Made As of the 28 Day of January, 2022 

By And Between RenovaCare Inc., And Histocell
S.L. (the “Agreement”)

 

 

PROPOSAL
OUTLINE FOR THE RESEARCH

 

All capitalized terms used in this Schedule 1 and
not otherwise defined shall have the meaning ascribed thereto in the Agreement.

 

Project Title:
    Development and Evaluation of [****] 

 

 

	Spray Device Company:	RenovaCare, Inc. Scottsdale, Arizona USA
	 	 
	Allogenic Cell Company: 	HistoCell S.L. Derio, Bizkaia Spain
	 	 
	Investigators: 	Drs. Roger Esteban-Vives (RenovaCare) and Begoña Castro (HistoCell)
	 	 
	Project start date:	Effective Date, subject to funding criteria set forth in the Agreement
	 	 
	Term:	[****] years commencing on the Effective Date
	 	 
	Proposed Experiments:	[****].

 

		Funders:	Funding for the Research and Collaboration will be sought from external third-party research funding
organizations [****] or other third-party funding organizations or through Internal Funding by both Parties as may be agreed
in writing.

 

		Summary	

 

Skin grafting with
autologous and allogenic skin tissues has been the main stay treatment of partial- and full-thickness burn wounds for centuries. The advent
of sheets of allogenic skin cultivated in vitro and biopolymers used as matrices and meshed to provide ultrastructural support
have supplanted skin grafting to certain extent. However repeated surgeries and scarring are sequential sequalae of these forms of burn
treatment. Most recently autologous skin cell therapy has been introduced as an alternative treatment that may offer a permanent single
procedure for burn wounds without scarring in a definitive care setting (i.e., operation room surgeries). By combining enzymatic
tissue digestion to render skin and pluripotent stem cells that are administered as a gentle, ultrafine mist with a medical spray device
(e.g., SkinGunTM), partial-thickness second-degree burn wounds may be treated effectively.

 

Despite these advancements,
wound treatment is deficient in several areas. Treatment of full-thickness wounds in definitive settings may require stem cells from a
different tissue source to afford stem cells that can facilitate healing of damaged skin, neuronal, vascular, muscular, and other tissues.
Adipose-derived stem cells are shown in clinical studies to provide stem cells that may differentiate into the required cells for these
types of wounds. [****] however, a [****]may be effective, as shown in clinical case studies for burn wounds. Lastly there
is not an effective treatment of warfighters with burn and trauma wounds that may be administered in the field to facilitate rapid wound
healing and keep the warfighter in the theater of operation until definitive care can be provided.

 

    
	20

     

    

The Collaboration
project poses a set of experiments and development of a new [****]. Through the Collaboration the Parties initially will seek to
develop human [****]. If successful it is contemplated that the Parties, in good faith, will negotiate the terms and conditions
of a Definitive Commercialization Agreement, as contemplated by the Agreement.

 

Then the Collaboration
moves into the clinical evaluation phase marked by proof-of-concept and pivotal clinical trials in the U.S. that evaluate the safety,
feasibility, and efficacy of [****]. Additionally, [****]. Lastly evaluation of wound care with special antioxidant dressings
(i.e.,/ [****]) will be evaluated with this new [****]therapy in separate arms of these clinical trials.

 

Partial funding for
the Collaboration will be sought from external third-party research funding organizations (e.g., [****]). Both Parties agree
to pursue actively and on a regular basis their participation in private or public initiatives, programs, grants etc which may provide
any additional third-party funds to the Collaboration.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

21Exhibit 4.1

VOTING SUPPORT AGREEMENT
THIS VOTING SUPPORT AGREEMENT ("Agreement") is dated as of January 31, 2022, by and between Verano Holdings Corp., a corporation existing under the laws of the Province of British Columbia (the "Purchaser"), and the undersigned beneficial owner of the securities listed on Schedule A attached hereto (the "Shareholder").
WHEREAS, the Shareholder is a director and/or officer of Goodness Growth Holdings, Inc., a corporation existing under the laws of the Province of British Columbia (the “Company”), and the beneficial owner of certain issued and outstanding shares in the capital of the Company (collectively, the “Company Shares”), as described more particularly on Schedule A hereto (together with any additional Company Shares acquired after the date hereof, the "Subject Shares");
WHEREAS, the Purchaser is, concurrently herewith, entering into an arrangement agreement (the "Arrangement Agreement") with the Company pursuant to which, among other things, the Purchaser will acquire all of the issued and outstanding shares of the Company in the manner provided for by a plan of arrangement under the provisions of the Business Corporations Act (British Columbia) (the "BCBCA"); and
WHEREAS, as a condition to its willingness to enter into the Arrangement Agreement and in order to induce the Purchaser to enter into the Arrangement Agreement, the Shareholder is willing to execute and deliver this Agreement and to make certain representations, warranties, covenants and agreements with respect to the Subject Shares.
NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows:
ARTICLE 1​
INTERPRETATION 
	1.1	All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Arrangement Agreement. All references herein to the Arrangement Agreement or any portion thereof refer to the Arrangement Agreement as amended, modified, restated or waived. The word "it" in reference to the Shareholder is used as a generic identifier and shall be deemed to mean "he" or "she" or words of similar import, as applicable.

	1.2	As used in this Agreement:

"Adverse Proposal" means: (a) any Acquisition Proposal, (b) any change in a majority of the board of directors of the Company (other than as contemplated in the Arrangement Agreement), (c) any amendment to the Company’s organizational documents (other than as contemplated in the Arrangement Agreement), (d) any material change in the capitalization of the Company or the Company’s corporate structure or in any material terms of any security of the Company, or otherwise obligating the Company to grant any security (other than as contemplated in the Arrangement Agreement), or (e) any other matter that would reasonably be expected to impede, interfere with, delay, postpone, discourage or adversely affect the Plan of Arrangement or any of the other transactions contemplated by the Arrangement Agreement or this Agreement, but for greater certainty, a Superior Proposal shall not be an Adverse Proposal.

"Affiliate" has the meanings set forth in Rule 12b-2 promulgated under the Exchange Act or the BCBCA and shall include all persons or entities that at any time during the term of this Agreement become Affiliates of any Person referred to in this Agreement.
"Associate" has the meanings set forth in Rule 12b-2 promulgated under the Exchange Act or the BCBCA and shall include all persons or entities that at any time during the term of this Agreement become Associates of any Person referred to in this Agreement.
"Encumbrances" means any security interests, liens, claims, pledges, options, rights of first refusal, co-sale rights, agreements, limitations on the Shareholder's voting rights, charges and other encumbrances of any nature (other than any encumbrances created by this Agreement or arising under applicable federal and state securities laws).
"Exchange Act" means the U.S. Securities Exchange Act of 1934, as amended.
ARTICLE 2​
COVENANTS OF THE SHAREHOLDER
	2.1	The Shareholder hereby covenants and irrevocably agrees that the Shareholder shall, from the date hereof until the earlier of (i) the Effective Time, and (ii) the termination of this Agreement pursuant to Article 6 (such earlier time, the "Expiration Time"): 

		(a)	direct all Affiliates and Associates of the Shareholder to take the actions under this Agreement;

		(b)	not directly or indirectly option for sale, offer, sell, gift, assign, transfer, exchange, assign, dispose of, pledge, tender, encumber, grant a security interest in, hypothecate or otherwise convey any of the Subject Shares, or any right or interest therein (legal or equitable) ("Transfer"), to any Person or agree to do any of the foregoing;

		(c)	except to the extent contemplated by this Agreement, not directly or indirectly grant any proxy, power of attorney or other right to vote the Subject Shares, or enter into any voting agreement, voting trust, vote pooling or other agreement or commitment with respect to the right to vote, call meetings of the Company Shareholders or give consents or approval of any kind with respect to any of the Subject Shares or agree to do any of the foregoing;

		(d)	not directly or indirectly vote or cause to be voted any of the Subject Shares in respect of any proposed action by the Company in a manner which might reasonably be expected to prevent or materially delay the successful completion of the Arrangement or the other transactions contemplated by the Arrangement Agreement;

		(e)	not directly or indirectly take any action which might be reasonably expected to impede, prevent or materially delay the approval of the Arrangement Resolution by the Company Shareholders;

		(f)	not bring, or threaten to bring, any suit or proceeding for the purpose of, or which has the effect of, directly or indirectly, stopping, preventing, impeding, delaying or varying the Plan of Arrangement or the other transactions contemplated by the Arrangement Agreement or any aspect thereof, including not exercising any securityholder rights or remedies available at common law or pursuant to applicable securities laws;

2
​

		(g)	not directly or indirectly take any action that would make any representation or warranty contained herein untrue or incorrect or that would have the effect of impairing the ability of the Shareholder to perform his, her or its obligations under this Agreement or preventing or delaying the consummation of any of the transactions contemplated hereby;

		(h)	not exercise any Dissent Rights;

		(i)	subject to Section 2.3 hereto, if the Arrangement Agreement is amended or terminated such that the transactions (or any of them) contemplated by the Arrangement Agreement are to be accomplished by means of an alternative transaction structure other than as currently contemplated in the Arrangement Agreement whereby the Purchaser would offer to acquire all of the Company Shares, that complies with the following terms and conditions: (i) the amended transaction would provide the Shareholder with consideration equivalent to or greater than, on an after-tax basis, the transactions set out in the Arrangement Agreement, and (ii) the consummation of the amended transaction would not take materially longer than the consummation of the transactions set out in the Arrangement Agreement (any such transaction is referred to as an "Alternative Transaction"), support the completion of the Alternative Transaction in the same manner as this Agreement provides with respect to the Arrangement, including, in the case of a take-over bid, by causing all of the Subject Shares to be validly tendered in acceptance of such take-over bid together with the letter of transmittal and, if applicable, notice of guaranteed delivery, and any other documents required in accordance with such take-over bid, and not withdraw the Subject Shares from such take-over bid except with the consent of the Purchaser; and

		(j)	not do indirectly that which the Shareholder may not do directly by the terms of this Section 2.

	2.2	For greater certainty, any Company Subordinate Voting Shares, Company Multiple Voting Shares or Company Super Voting Shares or other securities of the Company that the Shareholder purchases or with respect to which the Shareholder otherwise acquires beneficial ownership (as defined in the BCBCA or in Rule 13d-3 under the Exchange Act) after the date of this Agreement and prior to the Expiration Time, including by reason of any vesting of restricted stock, stock split, stock dividend, reclassification, recapitalization or other similar transaction or pursuant to the exercise of options, convertible securities or warrants to purchase such shares, the conversions of any Company Shares into other classes of Company Shares or the conversion of any debt for such shares shall be subject to the terms and conditions of this Agreement to the same extent as if they comprised a portion of the Subject Shares and shall be deemed to be included in the Subject Shares for the purposes hereof.

	2.3	The Purchaser acknowledges and agrees that: (a) the Shareholder is bound hereunder solely in its capacity as a securityholder of the Company and that the provisions hereof shall not be deemed or interpreted to bind the Shareholder in its capacity as a director or officer of the Company (if the Shareholder holds such office); and (b) nothing in this Agreement will prevent the Shareholder from acting in accordance with the exercise of his or her fiduciary duties or duty to act in the best interests of the Company as a director or officer of the Company or the Company’s Subsidiaries, after considering the advice of external legal counsel.

3
​

ARTICLE 3​
AGREEMENT TO VOTE IN FAVOUR OF THE ARRANGEMENT RESOLUTIONS
	3.1	The Shareholder hereby covenants and irrevocably agrees, from the date hereof until the Expiration Time, except as permitted by this Agreement:

		(a)	to vote the Subject Shares, and, in the case of Subject Shares held by an Affiliate or Associate of the Shareholder, to cause any holder of record of Subject Shares to vote or to execute a written consent or consents with respect to the Subject Shares at the Company Meeting (or any adjournment or postponement thereof or at every other meeting of the Company Shareholders with respect to the Arrangement Resolution): (i) in favour of the Arrangement Resolution and any other matter necessary for the consummation of the Arrangement; (ii) against any Adverse Proposal; and (iii) against any action, proposal, transaction, agreement, or other matter that would reasonably be expected to impede, interfere with, delay, discourage, postpone or adversely affect the Plan of Arrangement or any of the transactions contemplated by the Plan of Arrangement;

		(b)	if the Shareholder is the holder of record of any of the Subject Shares, no later than five Business Days prior to the date of the Company Meeting, the Shareholder shall deliver or cause to be delivered to the Purchaser, a copy of the duly executed proxy or proxies in respect of the Subject Shares directing the holder of such proxy or proxies to vote in favour of the Arrangement Resolution and/or any matter that could be expected to facilitate the Arrangement;

		(c)	if the Shareholder is the beneficial owner of any of the Subject Shares, no later than five Business Days prior to the date of the Company Meeting, the Shareholder shall deliver or cause to be delivered to the Purchaser, a copy of the duly executed voting instruction form(s) delivered to the intermediary through which the Shareholder holds its beneficial interest in the Subject Shares instructing that the Subject Shares be voted at the Company Meeting in favour of the Arrangement Resolution and/or any matter that could be expected to facilitate the Arrangement;

		(d)	to name those individuals in such proxy or proxies, or voting instruction form(s), as are designated by the Company in the proxy statement accompanying the Company Circular; and

		(e)	not to tender for any bid or tender offer for the Company Shares or take any action (including the voting (or granting of a proxy to vote) of the Subject Shares) that may lead to or otherwise result in an Adverse Proposal.

ARTICLE 4​
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE SHAREHOLDER
	4.1	The Shareholder represents, warrants and, where applicable, covenants to the Purchaser as follows, and acknowledges that the Purchaser is relying upon these representations, warranties and covenants in connection with the entering into of this Agreement and the Arrangement Agreement:

		(a)	(i) the Shareholder (A) owns beneficially (as such term is defined in Rule 13d-3 under the Exchange Act) all of the Subject Shares set forth on Schedule A, and (B) will own 

4
​

			beneficially any additional Subject Shares acquired after the date of this Agreement, in each instance, free and clear of all Encumbrances, and (ii) except pursuant hereto, there (A) are no options, warrants or other rights, agreements, arrangements or commitments of any character to which the Shareholder is a party or subject relating to the pledge, disposition, Transfer or voting of any of the Subject Shares set forth on Schedule A, and there are no voting trusts or voting agreements with respect to such Subject Shares, and (B) there will not be any options, warrants or other rights, agreements, arrangements or commitments of any character to which the Shareholder is a party relating to the pledge, disposition, Transfer or voting of any of additional Subject Shares acquired after the date of this Agreement, and there will not be any voting trusts or voting agreements with respect to such additional Subject Shares;

		(b)	the Shareholder has the full power and authority and legal capacity to enter into, execute and deliver this Agreement and to perform fully the Shareholder's obligations hereunder and has received all requisite approvals to execute and deliver this Agreement and to perform its obligations hereunder and to complete the transactions contemplated in the Arrangement Agreement; 

		(c)	this Agreement has been duly and validly executed and delivered by the Shareholder and, constitutes a legal, valid and binding obligation, enforceable by the Purchaser against the Shareholder in accordance with its terms subject only to any limitation under bankruptcy, insolvency or other laws affecting the enforcement of creditors' rights generally and the discretion that a court may exercise in the granting of equitable remedies such as specific performance and injunction;

		(d)	none of the execution and delivery by the Shareholder of this Agreement or the completion or performance of the transactions contemplated hereby or the compliance by the Shareholder with the Shareholder's obligations hereunder will result in a breach of or constitute a default under any provision of: (i) any agreement or instrument to which the Shareholder is a party or by which the Shareholder or any of the Shareholder's property or assets is bound, (ii) any judgment, decree, order or award of any Governmental Entity against the Shareholder, or (iii) any law, statute, ordinance, regulation or rule applicable to the Shareholder, except in each case as would not reasonably be expected, either individually or in the aggregate, to impair the ability of the Shareholder to perform its obligations hereunder;

		(e)	the Subject Shares are, and will be at all times up until the Effective Time, free and clear of any Encumbrances that could adversely affect the Plan of Arrangement, the Arrangement Agreement, or the exercise or fulfillment of the rights and obligations of the Purchaser or the Shareholder under this Agreement or the Arrangement Agreement; 

		(f)	there are no legal proceedings in progress or pending before any Governmental Entity or, to the knowledge of the Shareholder, threatened against the Shareholder or its Affiliates or Associates that would reasonably be expected, either individually or in the aggregate, to  impair the ability of the Shareholder to enter into this Agreement and to perform its obligations hereunder; and

		(g)	no consent of the Shareholder’s spouse is necessary under any applicable Law in order for the Shareholder to enter into and perform its obligations hereunder.

5
​

ARTICLE 5​
REPRESENTATIONS, WARRANTIES OF THE PURCHASER
	5.1	The Purchaser represents and warrants to the Shareholder as follows and acknowledges that the Shareholder is relying upon these representations and warranties in connection with the entering into of this Agreement:

		(a)	the Purchaser has been duly formed and is validly existing under the laws of the Province of British Columbia and has the requisite corporate power and authority to enter into this Agreement and to perform its obligations hereunder;

		(b)	the execution and delivery of this Agreement and the completion by the Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action of the Purchaser and no other corporate proceedings on the part of the Purchaser are necessary to authorize the execution and delivery by it of this Agreement or the completion by the Purchaser of the transactions contemplated hereby; and

		(c)	this Agreement has been duly executed and delivered by the Purchaser and constitutes the legal, valid and binding obligation of the Purchaser enforceable against it in accordance with its terms subject only to any limitation under bankruptcy, insolvency or other laws affecting the enforcement of creditors' rights generally and the discretion that  court may exercise in the granting of equitable remedies such as specific performance and injunction.

ARTICLE 6​
TERMINATION 
	6.1	This Agreement shall terminate automatically, without any required notice, upon the earliest to occur of: (i) the Effective Time, (ii) the date upon which the Shareholder and the Purchaser mutually agree to terminate this Agreement; and (iii) the date on which the Arrangement Agreement is validly terminated in accordance with its terms.

ARTICLE 7​
DISCLOSURE 
	7.1	The Shareholder: (i) consents to the details of this Agreement being set out in the Company Circular and accompanying proxy statement and this Agreement being made publicly available, including by filing on SEDAR and EDGAR, as may be required pursuant to applicable securities laws or any Governmental Entity in connection with the Arrangement, (ii) consents to and authorizes the publication and disclosure by the Purchaser and the Company of its identity and holding of Subject Shares, the nature of its commitments and obligations under this Agreement and any other information, in each case that the Purchaser or the Company reasonably determines is required to be disclosed by applicable Law in any press release, or any other disclosure document in connection with the Arrangement and any transactions contemplated by the Arrangement Agreement, (iii) agrees promptly to give to the Purchaser and the Company any information either may reasonably require for the preparation of any such disclosure documents, including the Company Circular and accompanying proxy statement, and (iv) agrees to promptly notify the Purchaser and the Company of any required corrections with respect to any written information supplied by it specifically for use in any such disclosure document, if and to the extent that any such information shall have become false or misleading in any material respect. Except as contemplated by the immediately preceding sentence and as otherwise required by applicable 

6
​

		Laws or by any Governmental Entity or in accordance with the requirements of any stock exchange, no party shall make any public announcement or statement with respect to this Agreement without the approval of the other, which shall not be unreasonably withheld, conditioned or delayed.

ARTICLE 8​
GENERAL
	8.1	This Agreement shall become effective upon execution and delivery hereof by the Shareholder and the Purchaser.

	8.2	The Shareholder and the Purchaser shall, from time to time, promptly execute and deliver all such further documents and instruments and do all such acts and things as the other party may reasonably require to effectively carry out the intent of this Agreement.

	8.3	This Agreement shall not be assignable by any party without the prior written consent of the other parties. This Agreement shall be binding upon and shall enure to the benefit of and be enforceable by each of the parties hereto and their respective successors and permitted assigns.

	8.4	Time shall be of the essence of this Agreement.

	8.5	Any notice or other communication required or permitted to be given hereunder shall be sufficiently given if in writing, delivered or sent by telecopier or facsimile transmission or e-mail or similar means of recorded electronic communication:

​
		(a)	if to the Purchaser:

​
Verano Holdings Corp.
415 North Dearborn Street, 4th Floor
Chicago, Illinois 60654
Attention: George Archos, Chairman and Chief Executive Officer
Email:[REDACTED]
​
with a copy (which shall not constitute notice) to:
​
Dentons Canada LLP
77 King Street West, Suite 400
Toronto-Dominion Centre 
Toronto, Ontario M5K 0A1
Attention: Ora Wexler / Eric Foster
Email:[REDACTED]
​
		(b)	if to the Company:

​
Goodness Growth Holdings, Inc.
207 South 9th Street
Minneapolis, Minnesota 55402
Attention: Kyle E. Kingsley, Chief Executive Officer and Chairman
Email:[REDACTED]
​
with a copy (which shall not constitute notice) to:
​
DLA Piper (Canada) LLP
100 King Street West, Suite 6000
Toronto, Ontario M5X 1E2

7
​

Attention: Russel Drew
Email:[REDACTED]
​
and to:
​
DLA Piper LLP (US)‎
1251 Avenue of the Americas‎
New York, NY 10020‎
Attention:‎ Christopher Giordano ‎
E-mail:‎[REDACTED]
​
		(c)	In the case of the Shareholder:

To the address set forth on Schedule A attached hereto,
​
or to such other street address, individual or electronic communication number or address as may be designated by notice given by any party to the others. Any demand, notice or other communication given by personal delivery will be conclusively deemed to have been given on the day of actual delivery thereof and, if given by facsimile or electronic communication, on the day of transmittal thereof if given during the normal business hours of the recipient and on the following Business Day if not given during such hours on any day.
	8.6	This Agreement will be governed by, construed and interpreted and enforced in accordance with the laws of British Columbia and the federal laws of Canada applicable therein, without regard to the conflict of laws, rules or principles thereof (or any other jurisdiction to the extent such laws, rules or principles would direct a matter to another jurisdiction). Each of the Parties hereby irrevocably attorns and submits to the exclusive jurisdiction of the British Columbia courts situated in Vancouver, British Columbia in respect of all matters arising under and in relation to this Agreement, and irrevocably waives objection to the venue of any proceeding in such court or that such court provides an inconvenient forum.

	8.7	Each of the parties hereto agrees with the other that: (i) monetary damages may not be a sufficient remedy for any breach of this Agreement by any of the parties, (ii) in addition to any other remedies at law or in equity that a party may have, such party shall be entitled to seek equitable relief, including injunction and specific performance, in the event of any breach of the provisions of this Agreement, and (iii) any party that is a defendant or respondent shall waive any requirement for the securing or posting of any bond in connection with such remedy. Each of the parties hereby consents to any preliminary applications for such relief to any court of competent jurisdiction.

	8.8	If any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not irremediably affected in any manner materially adverse to any party hereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties hereto as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled according to their original tenor to the extent possible.

	8.9	This Agreement constitutes the entire agreement between the parties and supersedes all other prior agreements, understandings and undertakings, both written and oral, among the parties with respect to the subject matter hereof.

8
​

	8.10	The Shareholder confirms that it has had the opportunity to obtain independent legal advice regarding its rights, duties and obligations hereunder and the Shareholder has sought, or has willingly waived the right to seek independent legal advice regarding its respective rights, duties and obligations hereunder.

	8.11	This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute one and the same instrument, and it shall not be necessary in making proof of this Agreement to produce more than one counterpart.

[Signatures to follow]
​

9
​

IN WITNESS WHEREOF the parties have executed this Agreement as of the date first written above.
​
	​
	VERANO HOLDINGS CORP.‎

	​
	​
	By:
	​
(Signed) “Darren Weiss”

	​
	​
	​
	Name: Darren Weiss

		​
		Title: Chief Operating Officer and General Counsel

​
​

10
​

​
	​
	​

	​
	​
	​
	​

	​
	WITNESS
	​
	[Shareholder]

		​
		​

	​
	​
	​
	​

​
​
​

11
​

SCHEDULE A 
SHAREHOLDER AND SECURITIES INFORMATION
[REDACTED]

12
​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]